This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.00009-08v1 52/6/2239    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Moayeri, M. Articles by Karginov, V. A. PubMed PubMed Citation Articles by Moayeri, M. Articles by Karginov, V. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2008, p. 2239-2241, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.00009-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

In Vivo Efficacy of β-Cyclodextrin Derivatives against Anthrax Lethal Toxin

Bacterial Toxins and Therapeutics Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892,¹ Innovative Biologics, Inc., 13455 Sunrise Valley Dr., Suite 200, Herndon, Virginia 20171²

Received 2 January 2008/ Returned for modification 14 February 2008/ Accepted 17 March 2008

We evaluated the in vivo efficacy of three β-cyclodextrin derivatives that block the anthrax protective antigen pore. These compounds were at least 15-fold more potent than previously described β-cyclodextrins in protecting against anthrax lethal toxin in a rat model. One of the drugs was shown to protect mice from bacterial infection.

Published ahead of print on 31 March 2008.